Health Catalyst opened higher at $1.46, compared with its previous close of $1.43. In the last trading session, the stock traded between $1.34 and $1.48. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Health Catalyst is now worth
$ 2.75
Resulting in a loss of
$ 97.25 (97.25%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.08 (-5.24%)
Day High
$1.48
Day Low
$1.34
Day Open
$1.46
Prev Close
$1.43
Volume
6,57,057
1W Return
-15.05%
1M Return
-22.79%
3M Return
-23.19%
6M Return
-1.81%
1Y Return
-49.63%
Market Cap ($ Mn)
103
PE Ratio
-
PB Ratio
1.18
PEG Ratio
-
ROE
-53.37%
ROCE
-31.92%
EPS (TTM)
$0.53
1 Week
-15.05%
1 Month
-22.79%
3 Months
-23.19%
6 Months
-1.81%
9 Months
-31.91%
Health Catalyst Q3 revenue hits $56.3M, beats high-end guidance
Revenue of $56.3 million and adjusted EBITDA of $779,000 exceeded guidance ranges. Adjusted gross margin fell to 44.3% from 52.6% due to professional services pressure. Company is debt-free with $79 million in cash after Vitalware divestiture. Full-year revenue outlook reaffirmed at $246 million to $249 million.
7 days agoHealth Catalyst Q2FY26 Results: Revenue beats guidance, debt retired
Revenue hit $70.5 million in Q2 2026, beating the high end of guidance. Divested Vitalware for $147 million, retiring $160 million in debt. Eliminated ~$19 million in annual GAAP interest expense post-transaction. Full-year 2026 revenue guidance set at $246–$249 million. Adjusted EBITDA for Q2 reached $9.9 million, at top of guided range.
1mo agoHealth Catalyst grants 2.75 million RSUs to new CEO Simeon Kohl
Health Catalyst granted 2,747,385 RSUs to new CEO Simeon Kohl on September 14, 2026. Awards were made under Nasdaq Listing Rule 5635(c)(4) as an employment inducement. 915,975 RSUs vest in one year; the rest vest in eight quarterly installments. Mr. Kohl bought 59,000 shares at a weighted average price of $1.787188.
1mo agoHealth Catalyst to present at Wells Fargo healthcare conference
Health Catalyst management to speak at Wells Fargo conference. Event scheduled for September 9-10, 2026 in Boston. Company cites $2.8 billion in documented outcomes.
2mo agoWells Fargo lowers Health Catalyst price target to $1.5
Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on Health Catalyst (NASDAQ: HCAT). The price target was lowered from $1.75 to $1.5, reflecting a modest downward revision in valuation expectations.
3mo agoHealth Catalyst Q2 Results: Operating results due August 6, 2026 after market close
Health Catalyst, Inc. has announced it will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. A conference call to review the results is scheduled for 5:00 pm ET on the same day, accessible via U.S. dial-in (800-274-8461), international dial-in (203-518-9814), or live audio webcast at https://ir.healthcatalyst.com/. The call replay will remain available for approximately 90 days. The company describes itself as a healthcare intelligence firm backed by $2.8 billion in documented outcomes.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $506.04 | +0.32% | $1,05,708.21M | 14.01 | |
| $304.77 | -0.26% | $49,345.01M | 45.36 | |
| $292.97 | +0.93% | $23,316.90M | 10.31 | |
| $72.62 | +0.18% | $14,450.29M | 52.31 | |
| $79.43 | -1.38% | $14,087.55M | - | |
| $142.24 | -0.19% | $13,957.16M | 20.21 | |
| $22.22 | -2.29% | $11,935.03M | 11.93 | |
| $183.50 | +2.35% | $11,542.15M | 15.26 | |
| $186.19 | +0.59% | $10,862.51M | 27.11 | |
| $196.77 | +0.70% | $10,170.65M | 7.00 | |
| $103.03 | -0.49% | $8,522.13M | 34.79 | |
| $50.06 | +1.96% | $7,945.72M | 25.00 |
An investment of $100 made 5 years ago in Health Catalyst is now worth
$ 2.75
Resulting in a loss of
$ 97.25 (97.25%)
Note: Past profits do not guarantee future returns.
